17 completed, 5 recruiting, 4 active not recruiting, 3 terminated. 17 Phase 1, 13 Phase 2, 4 Phase 3, 1 Phase 4.
Follow Relapsed Multiple Myeloma: new trials by email Literature Review of Relapsed Multiple Myeloma trials Research Report on Relapsed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INfections in Patients Treated With CAR-T Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 290 | 2026-11-01 | 2026-07-20 | |
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma OPN-6602, Dexamethasone - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Opna Bio LLC | 130 | 2024-08-22 | 2026-05-19 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Descartes-15 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 4 | 2024-06-19 | 2025-11-24 |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Iberdomide, Carfilzomib, Daratumumab - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 2 | Recruiting | Benjamin T Diamond, MD | 30 | 2024-02-20 | 2026-03-11 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma Elotuzumab, Selinexor, and Dexamethasone (ESd) - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Tulane University School of Medicine | 2022-04-27 | 2022-05-04 | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide Belantamab mafodotin, Carfilzomib, Dexamethasone - Relapsed Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | PETHEMA Foundation | 60 | 2021-12-20 | 2026-05-11 |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Thomas Martin, MD | 5 | 2021-10-18 | 2026-02-20 |
| Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Rapid Infusion Isatuximab - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Thomas Martin, MD | 2021-05-28 | 2022-07-07 | |
| A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) Isatuximab-dexamethasone - Relapsed Multiple Myeloma | Phase 2 | Active not recruiting | EMN Trial Office S.r.l. Impresa Sociale | 50 | 2021-03-21 | 2026-09-11 |
| A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma ION251 - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 23 | 2021-01-20 | 2024-10-31 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 54 | 2020-12-21 | 2023-06-08 |
| Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use Relapsed Multiple Myeloma | Completed | Centre Hospitalier le Mans | 172 | 2020-08-04 | 2022-03-09 | |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma RO7297089 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Completed | Genentech, Inc. | 27 | 2020-07-08 | 2024-07-03 |
| Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Nivolumab, Ixazomib, Dexamethasone - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Terminated | Andrew Yee, MD | 2 | 2020-02-14 | 2023-08-21 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) REGN5459 - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Regeneron Pharmaceuticals | 43 | 2019-09-26 | 2026-05-04 |
Showing 20 of 33. Sign in to see all of them.
Multiple Myeloma (33) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Neoplasms, Plasma Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Blood Protein Disorders (1) · Bone Marrow Failure Disorders (1) · Burkitt Lymphoma (1) · Cardiovascular Diseases (1) · Cytokine Release Syndrome (1) · Dendritic Cell Sarcoma, Interdigitating (1)
Hemic and Lymphatic Diseases (33) · Blood Protein Disorders (32) · Cardiovascular Diseases (32) · Hematologic Diseases (32) · Hemorrhagic Disorders (32) · Hemostatic Disorders (32) · Immune System Diseases (32) · Immunoproliferative Disorders (32) · Lymphoproliferative Disorders (32) · Neoplasms (32) · Neoplasms by Histologic Type (32) · Paraproteinemias (32) · Vascular Diseases (32) · Neoplasms, Plasma Cell (31) · Lymphatic Diseases (6)
Dexamethasone (11) · carfilzomib (6) · Cyclophosphamide (4) · Lenalidomide (4) · daratumumab (4) · fludarabine (3) · Calcium Dobesilate (2) · fludarabine phosphate (2) · iberdomide (2) · isatuximab (2) · ixazomib (2) · 2-Methoxyestradiol (1) · Acetaminophen (1) · Antilymphocyte Serum (1) · Biopsy (1)
Amgen (4) · Genentech, Inc. (2) · Thomas Martin, MD (2) · Alfred Chung, MD (1) · Andrew Yee, MD (1) · Association for Training, Education, and Research in Hematology, Immunology, and Transplantation (1) · Benjamin T Diamond, MD (1) · CASI pharmaceuticals, Inc. (1) · CHU de Quebec-Universite Laval (1) · Cartesian Therapeutics (1) · Centre Hospitalier le Mans (1) · Ciusss de L'Est de l'Île de Montréal (1) · Dana-Farber Cancer Institute (1) · EMN Trial Office S.r.l. Impresa Sociale (1) · Herlev Hospital (1)
United States (19) · Canada (7) · France (4) · Spain (4) · Australia (3) · Belgium (3) · Bulgaria (3) · Czechia (3) · Greece (3) · Italy (3) · Poland (3) · Russia (3) · Austria (2) · Denmark (2) · Germany (2)
Alfred Chung, MD (1) · Andrew Yee, MD (1) · Anupama Kumar, MD (1) · Benjamin Diamond, MD (1) · Carl O Landgren, MD, PhD (1) · Denis-Claude Roy, MD PhD (1) · Dr Vincent Laroche, MD,FRCPC (1) · Guido Tricot, MD, PhD (1) · Hana Safah, MD (1)
PMID 17947482, PMID 23447001, PMID 23927993, PMID 24014245, PMID 25482145, PMID 27002117, PMID 27119237, PMID 28148715, PMID 28683766, PMID 28751562, PMID 28803351, PMID 29054911, PMID 31433920, PMID 32145111, PMID 33476575, PMID 34111952, PMID 36656461, PMID 36781774, PMID 37646657, PMID 37646660
2019 (2), 2016 (1)